Ewing Sarcoma Pipeline Review, H1 2017 - 25 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Ewing Sarcoma - Pipeline Review, H1 2017" report to their offering.

Ewing Sarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 8, 21 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 2 molecules, respectively.

Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Ewing Sarcoma - Overview
  3. Ewing Sarcoma - Therapeutics Development
  4. Ewing Sarcoma - Therapeutics Assessment
  5. Ewing Sarcoma - Companies Involved in Therapeutics Development
  6. Ewing Sarcoma - Drug Profiles
  7. Ewing Sarcoma - Dormant Projects
  8. Ewing Sarcoma - Discontinued Products
  9. Ewing Sarcoma - Product Development Milestones
  10. Appendix

Companies Mentioned

  • Amgen Inc
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Company
  • Cebiotex SL
  • Celgene Corp
  • Celldex Therapeutics Inc
  • CytRx Corp
  • EntreChem SL
  • Gradalis Inc
  • Incyte Corp
  • Leadiant Biosciences Inc
  • MacroGenics Inc
  • Merck & Co Inc
  • Merrimack Pharmaceuticals Inc
  • NanoSmart Pharmaceuticals Inc
  • NantKwest Inc
  • Novartis AG
  • Oncomatryx Biopharma SL
  • Oncternal Therapeutics Inc
  • Pfizer Inc
  • Pharma Mar SA
  • Recombio SL
  • Shionogi & Co Ltd
  • Tarveda Therapeutics Inc
  • Tesaro Inc

For more information about this report visit https://www.researchandmarkets.com/research/wjx6bv/ewing_sarcoma

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs